Summary
This 8-K filing from Merck & Co., Inc. (MRK) on May 29, 2003, primarily concerns Schering-Plough Corporation, a separate entity, and provides an update on a federal criminal investigation. Schering Corporation, a subsidiary of Schering-Plough, has been identified as a target of this investigation by the U.S. Attorney for the District of Massachusetts. The investigation focuses on four key areas: alleged inducements for the purchase of pharmaceutical products for federal healthcare programs, promotion of drugs for unapproved uses ("off-label"), submission of false pricing information to the government for Medicaid rebates, and potential document destruction and obstruction of justice. Investors should note that Merck & Co., Inc. is not the subject of this investigation; the filing relates to Schering-Plough and its subsidiary.
Key Highlights
- 1Schering Corporation, a subsidiary of Schering-Plough, is a target of a federal criminal investigation.
- 2The investigation by the U.S. Attorney for the District of Massachusetts covers four areas of concern.
- 3Allegations include providing remuneration to induce purchases for federal healthcare programs.
- 4Concerns also involve the sale of misbranded or unapproved drugs (off-label promotion).
- 5False pharmaceutical pricing information submitted to the government for Medicaid rebates is another focus.
- 6The investigation extends to potential document destruction and obstruction of justice.
- 7Schering-Plough and Schering Corporation are cooperating with the U.S. Attorney's Office.